MC
NTLA icon

Moors & Cabot’s Intellia Therapeutics NTLA Stock Holding History

Moors & Cabot’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2,800
Closed -$203K – 886
2022
Q1 		$203K Hold
2,800
– – 0.01% 772
2021
Q4 		$331K Buy
2,800
+800
+40% +$100K 0.02% 591
2021
Q3 		$267K Hold
2,000
– – 0.02% 642
2021
Q2 		$324K Buy
+2,000
New +$156K 0.02% 543
2019
Q2 		– Sell
-10,550
Closed -$184K – 570
2019
Q1 		$184K Buy
+10,550
New +$157K 0.03% 491
2018
Q4 		– Sell
-9,700
Closed -$275K – 553
2018
Q3 		$275K Sell
9,700
-500
-5% -$14.5K 0.03% 442
2018
Q2 		$279K Buy
+10,200
New +$247K 0.04% 431

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Moors & Cabot's NTLA Position: Q2 2022 in Review

Moors & Cabot sold out of Intellia Therapeutics (NTLA) in Q2 2022, closing a stake of 2,800 shares — an estimated $203K sold.

Moors & Cabot first reported a position in NTLA in Q2 2018 and held it in 7 quarters. The position peaked at $331K in Q4 2021. 299 funds tracked by Wall St. Rank hold NTLA as of Q2 2022.

  • Moors & Cabot reported no remaining Intellia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Moors & Cabot sold 2,800 Intellia Therapeutics shares in Q2 2022, an estimated $203K.
  • Moors & Cabot first reported a position in Intellia Therapeutics in Q2 2018 and held it in 7 quarters.
  • Moors & Cabot's Intellia Therapeutics position peaked at $331K in Q4 2021.
  • 299 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2022.

Based on Moors & Cabot's 13F filing for Q2 2022, filed 8 Aug 2022.